Published in Am J Physiol Heart Circ Physiol on October 10, 2002
Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol (2007) 1.33
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol (2005) 1.30
Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev (2004) 1.10
Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater (2014) 1.07
Exercise training reduces fibrosis and matrix metalloproteinase dysregulation in the aging rat heart. FASEB J (2010) 0.97
Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation. J Cell Mol Med (2012) 0.93
Circulating matrix metalloproteinase-2 and -9 enzyme activities in the children with ventricular septal defect. Int J Biol Sci (2013) 0.87
Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors. Circ Heart Fail (2009) 0.81
Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res (2012) 0.81
Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. Biomaterials (2015) 0.80
Association between plasma ADAMTS-7 levels and ventricular remodeling in patients with acute myocardial infarction. Eur J Med Res (2015) 0.80
Tissue inhibitor of metalloproteinase-1 and -3 improves cardiac function in an ischemic cardiomyopathy model rat. Tissue Eng Part A (2014) 0.79
Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. J Cell Mol Med (2011) 0.79
Expression of ADAM-15 in rat myocardial infarction. Int J Exp Pathol (2009) 0.78
Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling. Arch Physiol Biochem (2011) 0.77
TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice. Mol Metab (2015) 0.77
The Role of ADAMTS1 and Versican in Human Myocardial Infarction: A Postmortem Study. Lab Med (2016) 0.75
Microcurrent stimulation promotes reverse remodelling in cardiomyocytes. ESC Heart Fail (2016) 0.75
The role of MEKK1 in hypertrophic cardiomyopathy. Int Heart J (2010) 0.75
Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest (2006) 4.51
Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation (2002) 3.98
Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol (2005) 3.15
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med (2015) 3.11
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 2.76
Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells (2007) 2.45
New markers of inflammation and endothelial cell activation: Part I. Circulation (2003) 2.43
Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg (2002) 2.31
Intravascular and extravascular microvessel formation in chronic total occlusions a micro-CT imaging study. JACC Cardiovasc Imaging (2010) 2.17
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 2.16
Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol (2012) 2.11
Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation (2003) 2.03
Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation (2010) 2.02
Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02
Microplegia during coronary artery bypass grafting was associated with less low cardiac output syndrome: a propensity-matched comparison. Ann Thorac Surg (2013) 2.00
Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg (2003) 1.96
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation (2002) 1.94
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation (2004) 1.94
Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC Cardiovasc Imaging (2009) 1.94
Endothelial progenitor cells: new hope for a broken heart. Circulation (2003) 1.93
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab (2008) 1.79
South Asians and cardiovascular risk: what clinicians should know. Circulation (2006) 1.74
Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol (2006) 1.69
Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg (2005) 1.66
C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation (2004) 1.65
Histologic changes of nonbiodegradable and biodegradable biomaterials used to repair right ventricular heart defects in rats. J Thorac Cardiovasc Surg (2002) 1.64
Hybrid intravascular ultrasound and optical coherence tomography catheter for imaging of coronary atherosclerosis. Catheter Cardiovasc Interv (2012) 1.64
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation (2005) 1.60
Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation (2011) 1.58
An adult uterine hemangioblast: evidence for extramedullary self-renewal and clonal bilineage potential. Blood (2010) 1.56
Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. Can J Cardiol (2012) 1.56
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol (2013) 1.54
Glitazones and heart failure: critical appraisal for the clinician. Circulation (2003) 1.53
Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary. Can J Cardiol (2005) 1.53
Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol (2005) 1.53
Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation (2008) 1.52
Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg (2007) 1.50
New developments in the treatment of hypoplastic left heart syndrome. Pediatrics (2007) 1.49
Fundamentals of reperfusion injury for the clinical cardiologist. Circulation (2002) 1.49
The insulin cardioplegia trial: myocardial protection for urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg (2002) 1.48
Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg (2007) 1.48
Statin therapy prevents expansive remodeling in venous bypass grafts. Atherosclerosis (2012) 1.47
Serum-free differentiation of functional human coronary-like vascular smooth muscle cells from embryonic stem cells. Cardiovasc Res (2012) 1.47
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation (2005) 1.46
Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts. Circulation (2002) 1.45
Cardiac restoration: frontier or fantasy? Can J Cardiol (2005) 1.44
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation (2004) 1.43
Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg (2008) 1.42
Aged human cells rejuvenated by cytokine enhancement of biomaterials for surgical ventricular restoration. J Am Coll Cardiol (2012) 1.42
Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol (2002) 1.41
Relationship between initial treatment strategy and quality of life in patients with coronary chronic total occlusions. EuroIntervention (2014) 1.41
Myometrial cells induce angiogenesis and salvage damaged myocardium. Am J Physiol Heart Circ Physiol (2006) 1.40
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation (2012) 1.39
MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation (2012) 1.39
Visible angiographic complications predict short and long-term outcomes in patients with post-procedural creatine-phosphokinase elevation. Catheter Cardiovasc Interv (2010) 1.39
A first-in-man study of percutaneous myocardial cryotreatment in nonrevascularizable patients with refractory angina. Catheter Cardiovasc Interv (2009) 1.38
Vascular endothelial growth factor receptor upregulation in response to cell-based angiogenic gene therapy. Ann Thorac Surg (2005) 1.38